Citation: | LIU Jinzhao, ZHANG Xiangmei, ZHOU Yarong, LIU Yunjiang. Risk of Primary Lung Cancer in Breast Cancer Patients: A Systematic Review and Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(7): 733-737. DOI: 10.3971/j.issn.1000-8578.2021.20.1430 |
To systematically evaluate the risk of primary lung cancer in breast cancer patients.
A computer-based search was conducted for the English literatures about the risk of primary lung cancer in breast cancer patients in Medline, Scopus and Embase databases. Two researchers independently screened the literatures, extracted the data and assessed the risk of bias. The statistical analysis was performed using the Stata 15.5 software.
A total of 7 references were included, and the overall risk of primary lung cancer in female breast cancer patients was slightly higher than that in the general population (SIR: 1.18, 95%CI: 1.09-1.27). Subgroup analysis showed that the risk of lung cancer was significantly increased in women aged < 50 years after diagnosis of breast cancer (SIR: 1.99, 95%CI: 1.48-2.69).
Compared with the general population, the risk of primary lung cancer is increased in female breast cancer patients, especially in young women with breast cancer.
Competing interests: The authors declare that they have no competing interests.
[1] |
Jain V, Kumar H, Anod HV, et al. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer[J]. J Control Release, 2020, 326: 628-647. doi: 10.1016/j.jconrel.2020.07.003
|
[2] |
Cheng Y, Huang Z, Liao Q, et al. Risk of second primary breast cancer among cancer survivors: Implications for prevention and screening practice[J]. PLoS one, 2020, 15(6): e0232800. doi: 10.1371/journal.pone.0232800
|
[3] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
|
[4] |
Okamoto N, Morio S, Inoue R, et al. The risk of a second primary cancer occurring in five-year survivors of an initial cancer[J]. Jpn J Clin Oncol, 1987, 17(3): 205-213. http://europepmc.org/abstract/MED/3669364
|
[5] |
Burt LM, Ying J, Poppe MM, et al. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results[J]. Breast, 2017, 35: 122-129. doi: 10.1016/j.breast.2017.07.004
|
[6] |
Page MJ, McKenzie JE, Bossuyt PM, et al. Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines[J]. J Clin Epidemiol, 2020, 118: 60-68. doi: 10.1016/j.jclinepi.2019.11.010
|
[7] |
Yamada A, Komaki Y, Komaki F, et al. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis[J]. Lancet Oncol, 2018, 19(6): 758-767. doi: 10.1016/S1470-2045(18)30188-8
|
[8] |
DeVito NJ, Goldacre B. Catalogue of bias: publication bias[J]. BMJ Evid Based Med, 2019, 24(2): 53-54. doi: 10.1136/bmjebm-2018-111107
|
[9] |
Schwartz AG. Ragheb NE, Swanson GM, et al. Racial and age differences in multiple primary cancers after breast cancer: A population-based analysis[J]. Breast Cancer Res Treat, 1989, 14(2): 245-254. doi: 10.1007/BF01810741
|
[10] |
Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia[J]. Cancer Causes Control, 1997, 8(5): 764-770. doi: 10.1023/A:1018487506546
|
[11] |
Levi F, Te VC, Randimbison L, et al. Cancer risk in women with previous breast cancer[J]. Ann Oncol, 2003, 14(1): 71-73. doi: 10.1093/annonc/mdg028
|
[12] |
Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study[J]. J Clin Oncol, 2008, 26(8): 1239-1246. doi: 10.1200/JCO.2007.11.9081
|
[13] |
Lee KD, Chen SC, Chan CH, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(10): 2647-2655. doi: 10.1158/1055-9965.EPI-08-0109
|
[14] |
Cluze C, Delafosse P, Seigneurin A, et al. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study[J]. Eur J Cancer Prev, 2009, 18(5): 343-348. doi: 10.1097/CEJ.0b013e32832abd76
|
[15] |
Tabuchi T, Ito Y, Ioka A, et al. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data[J]. Cancer Sci, 2012, 103(6): 1111-1120. doi: 10.1111/j.1349-7006.2012.02254.x
|
[16] |
Ricceri F, Fasanelli F, Giraudo MT, et al. Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC)[J]. Int J Cancer, 2015, 137(4): 940-948. doi: 10.1002/ijc.29462
|
[17] |
Corso G, Veronesi P, Santomauro GI, et al. Multiple primary non-breast tumors in breast cancer survivors[J]. J Cancer Res Clin Oncol, 2018, 144(5): 979-986. doi: 10.1007/s00432-018-2621-9
|
[18] |
Wang R, Yin Z, Liu L, et al. Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6, 269 Women[J]. Front Oncol, 2018, 8: 427. doi: 10.3389/fonc.2018.00427
|
[19] |
Deng F, Li M, Shan WL, et al. Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer[J]. Oncol Lett, 2017, 13(4): 2359-2365. doi: 10.3892/ol.2017.5711
|
[20] |
He C, He Y, Luo H, et al. Cytoplasmic ERβ1 expression is associated with survival of patients with Stage Ⅳ lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs[J]. Oncol Lett, 2019, 18(1): 792-803. http://www.researchgate.net/publication/333058241_Cytoplasmic_ERb1_expression_is_associated_with_survival_of_patients_with_Stage_IV_lung_adenocarcinoma_and_an_EGFR_mutation_at_exon21_L858R_subsequent_to_treatment_with_EGFR-TKIs
|
[21] |
Rosell J, Nordenskjöld B, Bengtsson NO, et al. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen[J]. Acta Oncol, 2017, 56(4): 614-617. doi: 10.1080/0284186X.2016.1273547
|
[22] |
Burt LM, Ying J, Poppe MM, et al. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results[J]. Breast, 2017, 35(10): 122-129. http://www.ncbi.nlm.nih.gov/pubmed/28719811
|
[23] |
Grantzau T, Overgaard J. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: A systematic review and meta-analysis of population-based studies including 522, 739 patients[J]. Radiother Oncol, 2016, 121(3): 402-413. doi: 10.1016/j.radonc.2016.08.017
|
[24] |
DiMarzio P, Peila R, Dowling O, et al. Smoking and alcohol drinking effect on radiotherapy associated risk of second primary cancer and mortality among breast cancer patients[J]. Cancer Epidemiol, 2018, 57: 97-103. doi: 10.1016/j.canep.2018.10.002
|
[25] |
Smida T, Bruno TC, Stabile LP. Influence of estrogen on the NSCLC microenvironment: a comprehensive picture and clinical implications[J]. Front Oncol, 2020, 10: 137. doi: 10.3389/fonc.2020.00137
|
[26] |
Chlebowski RT, Wakelee H, Pettinger M, et al. Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial[J]. Clin Lung Cancer, 2016, 17(1): 10-17. e1. doi: 10.1016/j.cllc.2015.09.004
|
[27] |
Chu SC, Hsieh CJ, Wang TF, et al. Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study[J]. Cancer Epidemiol, 2017, 48: 22-28. doi: 10.1016/j.canep.2017.02.010
|
[28] |
He M, Yu W, Chang C, et al. Estrogen receptor α promotes lung cancer cell invasion via increase of and cross-talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways[J]. Mol Oncol, 2020, 14(8): 1779-1799. doi: 10.1002/1878-0261.12701
|
[29] |
Watanabe T, Honda T, Totsuka H, et al. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults[J]. Breast Cancer Res Treat, 2020, 182(2): 491-502. doi: 10.1007/s10549-020-05716-0
|
[30] |
Maxwell KN, Wenz BM, Kulkarni A, et al. Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers[J]. JCO Precis Oncol, 2020, 4: PO. 19.00301. http://www.researchgate.net/publication/343756451_Mutation_Rates_in_Cancer_Susceptibility_Genes_in_Patients_With_Breast_Cancer_With_Multiple_Primary_Cancers
|